Visugromab for Cancer-related Weight Loss
Visugromab in Cachexia International Trial
Recruiting
Phase 2
Phase 3
Interventional Study
Cancer-associated Cachexia
Pivotal Trial
This treatment is in the last trial phase before FDA approval.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Trial phase
- Phase 2/3
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 518 (estimated)
- Sponsor
- CatalYm GmbH · Industry
Who this trial is looking for
This trial is looking for people with certain types of cancer who have lost weight unexpectedly. Participants will receive either visugromab or a placebo every four weeks at a hospital or clinic to see if it helps them gain weight and improve their appetite and activity levels.
Are You a Good Fit for This Trial?
You may be able to join if
- I have lost weight.
- I have advanced cancer.
You may not be able to join if
- I am participating in another clinical trial.
- I have received any investigational treatment or device in the last 4 weeks.
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.
Check Your Eligibility
About This Trial
A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are:
* Does visugromab help participants put weight back on and have a better appetite?
* Does visugromab help participants move more and better?
* What medical problems do part…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Weight loss
* Advanced cancer
Exclusion Criteria:
* Participation in another interventional clinical trial, receipt of any investigational therapy or use of any investigational device within 4 weeks prior to screening and between screening and the first dose of investigation…
Contacts